Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multiple epidermal growth factor-like domains 8 (MEGF8) is a large single-pass transmembrane protein encoded by the MEGF8 gene and composed of either 2845 or 2778 amino acids (human isoforms). It features a diverse set of domains, including several EGF-like domains known for their roles in protein-protein interactions and signaling, a CUB domain typically implicated in developmental processes, and motifs such as the kelch repeat and laminin EGF-like modules that influence protein structure and cellular interactions. MEGF8 is well conserved across animal species and is expressed during critical periods of development, contributing to body patterning and limb formation. Mutations in MEGF8 (particularly SNPs) are causative for Carpenter syndrome subtype 2, a rare congenital disorder with multisystem involvement. There is currently no evidence that MEGF8 acts as a direct pharmacological or therapeutic target, nor that it serves as a biomarker in clinical practice.
Not applicable; drugs targeting MEGF8 are not reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple epidermal growth factor-like domains 8 (MEGF8).